Amneal Pharmaceuticals, Inc. Stock News

Amneal Pharmaceuticals Inc (NYSE: AMRX) announced topline data from the Phase 3 RISE-PD trial evaluating IPX-203 in patients with Parkinson's disease who have motor fluctuations.  Amneal plans to

Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q2 2021 Results - Earnings Call Transcript

Amneal (AMRX) delivered earnings and revenue surprises of 38.89% and 1.86%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q2 revenue of $535 million, an increase of 15% Y/Y, beating the consensus of $523.25 million. Sales growth was driven by Generic product launches, spe

Shares of Amneal Pharmaceuticals (NYSE:AMRX) moved higher by 0.6% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 92.31% year over year to $

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The stock price of Amneal Pharmaceuticals Inc (NYSE: AMRX) increased 8.8% today. This is why it happened.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval

10 Stocks to watch now trading under $10 with significant upside potential The post 10 Stocks Under $10 to Buy In July for the Rest of the Year appeared first on InvestorPlace. More From InvestorPlace

AMRX vs. ZTS: Which Stock Is the Better Value Option?

If you're looking for a cheap stock to buy, check out this list of 10 highly rated picks that are priced under $10.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its management team will virtually attend the following investor conferences: RBC

AMRX vs. ZTS: Which Stock Is the Better Value Option?

Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q1 2021 Results - Earnings Call Transcript

Amneal (AMRX) delivered earnings and revenue surprises of 11.11% and -2.81%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?